Oxidative Stress and Redox-Modulating Therapeutics in Inflammatory Bowel Disease

Arno R. Bourgonje*, Martin Feelisch, Klaas Nico Faber, Andreas Pasch, Gerard Dijkstra, Harry van Goor

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

145 Citations (Scopus)
86 Downloads (Pure)


Inflammatory bowel disease (IBD) is associated with the production of reactive species that target cysteine redox switches in proteins, thereby affecting gene regulation, DNA damage, ion transport, intermediary metabolism, and mitochondrial function. Precursors of reactive species are derived from organic and inorganic compounds and their cofactors, including amino acids, vitamins, oxygen, nitrite, and sulfate. Nutrition and the gut microbiome fuel this process to a significant extent. The production of reactive species in IBD is reflected by a reduction in systemic free thiols, the major components of the antioxidant machinery. Systemic free thiols are amenable to nutritional or therapeutic intervention. This opens up future avenues for therapeutic modulation of redox status in IBD.

Original languageEnglish
Pages (from-to)1034-1046
Number of pages13
JournalTrends in Molecular Medicine
Issue number11
Publication statusPublished - Nov-2020

Cite this